Baseline information, collection

The committee will formulate an error management strategy to address the specific needs of the plant based on the information collected during the baseline exercise. The strategy will address the following areas ... 

Behavior — The LC2MS set up presented in Figure 4.12 will continue to trigger the MS to collect the data files designated for LC System 2 even if System 2 fails. However, the files after the point of failure contain only baseline information and are easily distinguished. The data files for LC System 1 are not impacted by the failure of System 2. If stopping the injection for both systems is the preferred action for the failure of LC System 2, System 2 must be able to communicate the... 

Patient data collection is an extremely critical component of a value-added service. The information collected provides pharmacists with important baseline and monitoring parameters for patients. The amount and type of information needed from the patient or other health care providers may differ depending on the service, but nonetheless, this information is the foundation on which the other components of the service are built. Forms can be developed to help pharmacists collect this information (see Figs. 25-2 through 25-4). In addition, some consideration should be given to how this information will be stored (e.g., paper charts or electronic patient database). The information that should be collected from the patient includes demographic information, medical history, family history, and medication history. Since some of the information may need to be collected from other providers and health care institutions, an authorization to release medical information should be signed by the patient and kept as part of the chart (see Fig. 25-5). Lastly, pharmacists should ensure that their site is in compliance with the Health Insurance Portability and Accountability Act (HIPPA) and reinforce to their patients that the information they provide is confidential and secure at the pharmacy. 

Data must be available on what is normality for each biomarker. Because of the diversity of species involved, this is a good deal more complex than in the case where biochemical levels are used in the diagnosis of human health. Obviously, it is impossible to have data on all species. While there is a great deal of data available, there is a need for a centralized database to collect, verify, and validate this baseline information. 

Botanical and ecological study of these protected areas is also sparse only two studies have been published on the flora and vegetation of the National Park Aguaro-Guariquito (Montes et al., 1987 Susach, 1989) and a third, on the ecology of the inundated savanna types, is in preparation. In the National Park Capanaparo-Cinaruco, intensive botanical collections have been made, but the results have not yet been published. This lack of solid scientific baseline information is a common situation in many Venezuelan national parks and represents a serious obstacle to the elaboration of sound and applicable management plans. 

Assessments are both initial and ongoing. An initial assessment is made based on objective and subjective data collected when the patient is first seen in a hospital, outpatient clinic, health care provider s office, or other type of health care facility. The initial assessment usually is more thorough and provides a database (sometimes called baseline) from which later data can be compared and decisions made The initial assessment provides information that is analyzed to identify... 

Finding 4-1. A Phase 1 QRA for using a baseline incineration system at Pueblo has been completed, and the point estimation of the impact on public health indicates that the risk to the public due to accidental releases would be extremely low. The HRA for Pueblo has not yet been completed. Several additional analyses are being conducted to support operational and design decisions for a modified baseline process. It is not clear how the Army is going to use the collective risk information it has or is seeking and in what framework this information will be used. 

Cynthia forges ahead and starts her heart failure clinic. She successfully enrolls 250 patients in her service over the course of 1 year. At the end of the year, she conducts her cost-benefit analysis and asks the HMO for the same information that she collected at baseline (see Table 27-4). 

Collect basic data around how long it will take to complete the major steps or substeps. Fill in any times or piece-count information in the relevant steps (e.g., 10 orders/hour). Write the estimated process cycle times on the bottom of the baseline chart. (Cycle time is how long a step spends on one unit, not including how long the unit is in a queue waiting for work to be performed.)... 

Pharmacoeconomic baseline data should not be considered in isolation, but as one aspect of data that must be considered as a part of the whole. Once the burden of illness information is collected and analyzed, the development team must move to plan for ways to measure and document the clinical, economic and humanistic impact of the new pharmaceutical entity or other intervention. 

---